NASDAQ:MITO

Stealth BioTherapeutics Stock Forecast, Price & News

$1.38
0.00 (0.00 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.35
$1.40
50-Day Range
$1.31
$1.77
52-Week Range
$1.06
$2.58
Volume45,435 shs
Average Volume158,055 shs
Market Capitalization$78.72 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
30 days | 90 days | 365 days | Advanced Chart
Receive MITO News and Ratings via Email

Sign-up to receive the latest news and ratings for Stealth BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Stealth BioTherapeutics logo

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

1076th out of 2,220 stocks

Pharmaceutical Preparations Industry

506th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Stealth BioTherapeutics (NASDAQ:MITO) Frequently Asked Questions

Is Stealth BioTherapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stealth BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Stealth BioTherapeutics stock.
View analyst ratings for Stealth BioTherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Stealth BioTherapeutics?

Wall Street analysts have given Stealth BioTherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Stealth BioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Stealth BioTherapeutics?

Stealth BioTherapeutics saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 86,700 shares, a drop of 73.2% from the June 30th total of 323,400 shares. Based on an average daily trading volume, of 5,250,000 shares, the days-to-cover ratio is currently 0.0 days.
View Stealth BioTherapeutics' Short Interest
.

When is Stealth BioTherapeutics' next earnings date?

Stealth BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Stealth BioTherapeutics
.

How were Stealth BioTherapeutics' earnings last quarter?

Stealth BioTherapeutics Corp (NASDAQ:MITO) released its earnings results on Tuesday, May, 18th. The company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.01.
View Stealth BioTherapeutics' earnings history
.

How has Stealth BioTherapeutics' stock been impacted by Coronavirus?

Stealth BioTherapeutics' stock was trading at $1.5887 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MITO stock has decreased by 13.1% and is now trading at $1.38.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MITO?

2 equities research analysts have issued 1 year price targets for Stealth BioTherapeutics' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Stealth BioTherapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 117.4% from the stock's current price.
View analysts' price targets for Stealth BioTherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Stealth BioTherapeutics' key executives?

Stealth BioTherapeutics' management team includes the following people:
  • Ms. Irene P. McCarthy J.D., Pres ,CEO, Sec. & Director (Age 57)
  • Mr. Robert J. Weiskopf, Chief Financial Officer (Age 70)
  • Mr. Henry Hess, Chief Legal Counsel
  • Mr. Mike Malynn, VP of HR
  • Dr. Ben R. Bronstein, Chief Medical Officer (Age 71)
  • Dr. Brian D. Blakey, Chief Bus. Officer (Age 59)
  • Dr. W. Douglas Weaver, Chief Medical Officer
  • Mr. James R. Carr, Chief Clinical Devel. Officer (Age 58)
  • Dr. Marty P. Redmon Ph.D., Chief R&D Officer (Age 59)

Who are some of Stealth BioTherapeutics' key competitors?

What other stocks do shareholders of Stealth BioTherapeutics own?

When did Stealth BioTherapeutics IPO?

(MITO) raised $81 million in an initial public offering (IPO) on Friday, February 15th 2019. The company issued 6,200,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and BMO Capital Markets acted as the underwriters for the IPO and Nomura was co-manager.

What is Stealth BioTherapeutics' stock symbol?

Stealth BioTherapeutics trades on the NASDAQ under the ticker symbol "MITO."

How do I buy shares of Stealth BioTherapeutics?

Shares of MITO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stealth BioTherapeutics' stock price today?

One share of MITO stock can currently be purchased for approximately $1.38.

How much money does Stealth BioTherapeutics make?

Stealth BioTherapeutics has a market capitalization of $78.72 million and generates $21.09 million in revenue each year. The company earns $-57,460,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How many employees does Stealth BioTherapeutics have?

Stealth BioTherapeutics employs 29 workers across the globe.

What is Stealth BioTherapeutics' official website?

The official website for Stealth BioTherapeutics is www.stealthbt.com.

Where are Stealth BioTherapeutics' headquarters?

Stealth BioTherapeutics is headquartered at 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466.

How can I contact Stealth BioTherapeutics?

Stealth BioTherapeutics' mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company can be reached via phone at 617-600-6888 or via email at [email protected]


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.